In conclusion, we developed a unique single-agent mRNA nanomedicine that takes advantage of the discovered GSDM-mediated pyroptosis pathway and LNP-meditated mRNA delivery system to improve cancer immunotherapy. Here, GSDMA is linked to cancer.